547741-72-0
547741-72-0
Chemical Structure
Abarelix Acetate
Synonym(s): PPI 149 Acetate; R 3827 Acetate
- CAS No.: 547741-72-0
- Formula:C74H99ClN14O16
- Molecular Weight:1476.12
IUPAC Name: (R)-N1-((S)-1-(((S)-1-((S)-2-(((R)-1-amino-1-oxopropan-2-yl)carbamoyl)pyrrolidin-1-yl)-6-(isopropylamino)-1-oxohexan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-2-((2S,5S,8R,11R,14R)-11-(4-chlorobenzyl)-2-(4-hydroxybenzyl)-5-(hydroxymethyl)-3-methyl-14-(naphth
InChIKey: ZRHCGBCCWJPSQF-JOOIWXSYSA-N
SMILES: CC(O)=O.CC(C[C@@H](C(N[C@H](C(N1CCC[C@H]1C(N[C@@H](C(N)=O)C)=O)=O)CCCCNC(C)C)=O)NC([C@H](NC([C@@H](N(C([C@@H](NC([C@H](NC([C@H](NC([C@H](NC(C)=O)CC2=CC=C3C=CC=CC3=C2)=O)CC4=CC=C(Cl)C=C4)=O)CC5=CN=CC=C5)=O)CO)=O)C)CC6=CC=C(O)C=C6)=O)CC(N)=O)=O)C
Biological Activity: Abarelix Acetate (PPI 149 Acetate; R 3827 Acetate) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer research[1].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Abarelix Acetate | 99.89% | Abarelix Acetate (PPI 149 Acetate; R 3827 Acetate) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Teverelix | Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ganirelix acetate | 99.19% | Ganirelix acetate (Ganirest) is a competitive and selective gonadotropin-releasing hormone (GnRH) antagonist. Ganirelix acetate blocks endogenous GnRH-induced release of luteinizing hormone (LH) and follicle-stimulating hormone. Ganirelix acetate antagonizes Prostaglandin E2 (HY-101952)-induced detrusor overactivity and enhances Carbachol (HY-B1208)-induced detrusor contraction. Ganirelix acetate is applicable to research related to female infertility and detrusor overactivity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
A-75998 | A-75998 is an antagonist of luteinizing hormone-releasing hormone (LHRH). A-75998 can be used in the research of diseases such as hormone-sensitive cancers and endometriosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Abarelix | 99.72% | Abarelix (R3827; PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer treatment. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acyline | 99.52% | Acyline, a GnRH peptide analogue, is a GnRH antagonist that inhibits gonadotropin and testosterone (T) levels. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ozarelix | Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cetrorelix | 99.82% | Cetrorelix (SB-75) is a competitive gonadotropin-releasing hormone receptor (GnRHR) antagonist with a Kd of 0.19 nM. Cetrorelix inhibits the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby suppressing the secretion of downstream sex steroids. Cetrorelix prevents ovulation, induces reversible reproductive shutdown and azoospermia, reduces ovarian fibrosis, improves superovulation outcomes, and inhibits chemotherapy-induced mitochondria-dependent apoptosis. Cetrorelix is applicable for fertility assistance research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cetrorelix acetate | 99.98% | Cetrorelix (SB-75) acetate is a competitive gonadotropin-releasing hormone receptor (GnRHR) antagonist with a Kd of 0.19 nM. Cetrorelix acetate inhibits the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby suppressing the secretion of downstream sex steroids. Cetrorelix acetate prevents ovulation, induces reversible reproductive shutdown and azoospermia, reduces ovarian fibrosis, improves superovulation outcomes, and inhibits chemotherapy-induced mitochondria-dependent apoptosis. Cetrorelix acetate is applicable for fertility assistance research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cetrorelix diacetate | Cetrorelix (SB-75) diacetate is a competitive gonadotropin-releasing hormone receptor (GnRHR) antagonist with a Kd of 0.19 nM. Cetrorelix diacetate inhibits the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby suppressing the secretion of downstream sex steroids. Cetrorelix diacetate prevents ovulation, induces reversible reproductive shutdown and azoospermia, reduces ovarian fibrosis, improves superovulation outcomes, and inhibits chemotherapy-induced mitochondria-dependent apoptosis. Cetrorelix diacetate is applicable for fertility assistance research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ganirelix | 99.88% | Ganirelix is a competitive and selective gonadotropin releasing hormone (GnRH) antagonist. Ganirelix prevents endogenous GnRH from inducing luteinising hormone (LH) and follicle stimulating hormone relea. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
